Less than a year after it picked up non-exclusive access to Alnylam Pharmaceuticals’ portfolio of RNAi-related intellectual property and acquired the RNAi-drug developer’s German subsidiary, Roche is on track to move its first RNAi-based drug candidates into the clinic in 2010, according to a senior company official.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.